FDA Authorizes Soligenix’s Pivotal Phase 3 Clinical Trial for Pediatric Crohn’s Disease Therapy

FDA Authorizes Soligenix’s Pivotal Phase 3 Clinical Trial for Pediatric Crohn’s Disease Therapy
Biopharmaceutical company Soligenix, Inc. recently announced in a news release that the U.S. Food and Drug Administration (FDA) has authorized a pivotal Phase 3 clinical trial to assess the efficacy of its drug SGX203 as a therapy for pediatric Crohn’s disease. Pediatric Crohn’s disease is a chronic inflammatory bowel disease characterized by inflammation across the lining

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *